VKTX Viking Therapeutics Inc

$26.01

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 6/21/2025

About Viking Therapeutics Inc

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing new therapies for metabolic and endocrine disorders. The company is headquartered in San Diego, California.

Website: https://www.vikingtherapeutics.com

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1607678
Address
12340 EL CAMINO REAL, SUITE 250, SAN DIEGO, CA, US
Valuation
Market Cap
$2.69B
P/E Ratio
nan
PEG Ratio
-0.03
Price to Book
3.05
Performance
EPS
$-1.01
Dividend Yield
Profit Margin
0.00%
ROE
-17.90%
Technicals
50D MA
$27.47
200D MA
$47.72
52W High
$81.86
52W Low
$18.92
Fundamentals
Shares Outstanding
112M
Target Price
$95.44
Beta
0.83

VKTX EPS Estimates vs Actual

Estimated
Actual

VKTX News & Sentiment

Jun 20, 2025 • Zacks Commentary NEUTRAL
Viking Therapeutics, Inc. ( VKTX ) Dips More Than Broader Market: What You Should Know
In the most recent trading session, Viking Therapeutics, Inc. (VKTX) closed at $26.01, indicating a -1.03% shift from the previous trading day.
Jun 18, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Can Ozempic, Wegovy Drive Further Growth for NVO in the Obesity Space?
Novo Nordisk sees soaring demand for Ozempic and Wegovy as label expansions and manufacturing boosts fuel obesity market gains.
Jun 18, 2025 • Motley Fool NEUTRAL
Missed Out on Eli Lilly's 480% Gains Over the Past 5 Years? These GLP-1 Stocks Still Have Plenty of Upside.
Eli Lilly ( NYSE: LLY ) has been one of the hottest healthcare stocks to own in recent years, thanks in large part to the success of its incredibly successful GLP-1 agonist drugs, which help patients with diabetes and weight loss.
Jun 16, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Novo Nordisk Stock Rises 6% in a Week: What Should Investors Do?
NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.
Jun 16, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Brokers Suggest Investing in Viking Therapeutics ( VKTX ) : Read This Before Placing a Bet
According to the average brokerage recommendation (ABR), one should invest in Viking Therapeutics (VKTX). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
Jun 16, 2025 • Motley Fool SOMEWHAT-BULLISH
Are These 2 High-Flying Growth Stocks Still Worth Buying After Recent Pullbacks?
When markets get jittery, high-growth stocks often take the biggest hits. But for investors with a stomach for volatility and an eye for transformative potential, these pullbacks can create exceptional opportunities.Last Friday's market turbulence sent the S&P 500 down 1.13%, with growth stocks ...
Sentiment Snapshot

Average Sentiment Score:

0.193
50 articles with scored sentiment

Overall Sentiment:

Bullish

VKTX Reported Earnings

Apr 22, 2025
Mar 31, 2025 (Pre market)
-0.1 Surprise
  • Reported EPS: $-0.41
  • Estimate: $-0.31
  • Whisper:
  • Surprise %: -31.7%
Feb 05, 2025
Dec 31, 2024 (Post market)
-0.04 Surprise
  • Reported EPS: $-0.32
  • Estimate: $-0.28
  • Whisper:
  • Surprise %: -14.3%
Oct 23, 2024
Sep 30, 2024 (Post market)
0.03 Surprise
  • Reported EPS: $-0.22
  • Estimate: $-0.25
  • Whisper:
  • Surprise %: 12.0%
Jul 24, 2024
Jun 30, 2024 (Post market)
0.07 Surprise
  • Reported EPS: $-0.20
  • Estimate: $-0.27
  • Whisper:
  • Surprise %: 25.9%
Apr 24, 2024
Mar 31, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $-0.26
  • Estimate: $-0.28
  • Whisper:
  • Surprise %: 7.1%
Feb 07, 2024
Dec 31, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.25
  • Whisper:
  • Surprise %: 0.0%
Oct 25, 2023
Sep 30, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.23
  • Estimate: $-0.22
  • Whisper:
  • Surprise %: -4.5%
Jul 26, 2023
Jun 30, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $-0.19
  • Estimate: $-0.19
  • Whisper:
  • Surprise %: 0.0%
Apr 26, 2023
Mar 31, 2023 (Post market)
-0.01 Surprise
  • Reported EPS: $-0.25
  • Estimate: $-0.24
  • Whisper:
  • Surprise %: -4.2%

Financials